Annexon Inc logo

Annexon Inc

ANNX
Healthcare|Biotechnology|USA
$5.79
-0.14 (-2.36%)
Tangible Book
$1.26
Earnings Power
$0.88

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 44.35, 192.46, 388.51, 861.54 ], "ebit_estimate": [ -200.64, -192.4, -18.97, 248.05, 654.75 ], "ebitda_estimate": [ -201.99, -209.42, -198.15, null, null ], "net_income_estimate": [ -188.52, -176.71, -5.7, 303.4, 663.4 ], "per_share_eps_estimate": [ -0.94, -0.78, 0.1, 0.96, 2.35 ], "eps_nri_estimate": [ -0.96, -0.82, -0.02, 1.11, 2.8 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -189.9, -185.85, 2.55, 334.65, 767.17 ], "operating_cash_flow_per_share_estimate": [ -0.86, -0.47, null, null, null ], "roa_estimate": [ -78.4, -140.4, null, null, null ], "roe_estimate": [ -112.75, -226.5, null, null, null ], "gross_margin_estimate": [ 87.5, 85, 84, 88.5, 92 ], "operating_cash_flow_estimate": [ -166.04, -91.27, null, null, null ], "pettm_estimate": [ 0, 0, 57.95, 6.04, 2.47 ], "long_term_growth_rate_mean": 70.56, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 70.56, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 52.02, "future_ebitda_estimate_growth": 1.96, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 66.27, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 1.73, 1.8, 2.89, 7.06 ], "ebit_estimate": [ -49.74, -52.37, -55.18, -53.03, -60.8, -66.45, -71.13 ], "ebitda_estimate": [ -49.07, -52.3, -55.89, null, null, null, null ], "net_income_estimate": [ -45.79, -48.51, -50.28, -50, -57.96, -64.14, -69.03 ], "per_share_eps_estimate": [ -0.23, -0.24, -0.23, -0.23, -0.26, -0.28, -0.2 ], "eps_nri_estimate": [ -0.24, -0.25, -0.25, -0.23, -0.26, -0.28, -0.2 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -45.96, -48.35, -50.35, -50, -57.96, -64.14, -69.03 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 70.56, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 70.56, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 52.02, "future_ebitda_estimate_growth": 1.96, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 66.27, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }